Market revenue in 2023 | USD 1,216.6 million |
Market revenue in 2030 | USD 3,674.5 million |
Growth rate | 17.1% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.74% in 2023. Horizon Databook has segmented the North America crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous advanced biotechnological research in agriculture and a strong regional economy have resulted in North America’s leading share in the global market. The presence of several government initiatives in the U.S. and Canada supports biotechnological research in agriculture and introduction of CRISPR based plant products.
Moreover, several pharmaceuticals and seed companies are investing in growth strategies, such as acquisitions, partnerships, and collaborations, to boost the market for pharmaceuticals & plant breeding, which can help boost the demand for CRISPR technologies in these industries.
For instance, in June 2019, Vertex Pharmaceuticals stated that it planned to expand its presence in gene editing by developing novel treatments for Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America crispr and cas genes market , including forecasts for subscribers. This continent databook contains high-level insights into North America crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account